Enveric Biosciences Files Portfolio of Patent Applications for Tryptamine-Based MoleculesPRNewsWire • 03/01/22
Enveric Biosciences collaborates with University of Calgary to establish clinical trial for EVM-101 in cancer related distressProactive Investors • 02/17/22
Enveric Biosciences and University of Calgary Collaborate on a Groundbreaking Clinical Trial for EVM-101 in Cancer Related DistressPRNewsWire • 02/17/22
Enveric Biosciences announces closing of $10M underwritten public offeringProactive Investors • 02/15/22
Enveric Biosciences advancing clinical plans as it announces two new molecules to treat osteoarthritis and other pain conditionsProactive Investors • 02/08/22
Enveric Biosciences Files Provisional Patent For CBD+Celecoxib Conjugate For OsteoarthritisBenzinga • 02/08/22
Enveric Biosciences Announces Successful Synthesis and Filing of Provisional Patent for EV104 - Cannabinoid + Celecoxib ConjugatePRNewsWire • 02/08/22
Enveric Biosciences to Participate in Upcoming Investor Conferences in February 2022PRNewsWire • 01/27/22
Enveric Biosciences CEO says company to focus on drug development, drug discovery, intellectual property strategy in 2022Proactive Investors • 01/18/22
Enveric Biosciences CEO, Dr. Joseph Tucker, Provides 2021 Year in Review and 2022 Outlook in Letter to ShareholdersPRNewsWire • 01/18/22
Enveric Biosciences to Participate in the H.C. Wainwright BioConnect Conference on January 10-13, 2022PRNewsWire • 01/06/22
Enveric Biosciences to Participate in the H.C. Wainwright 2nd Annual Psychedelics Virtual Conference on December 6thPRNewsWire • 11/29/21
Enveric Biosciences' CBD-Based Product Reduces Dermatitis Severity In Animal StudyBenzinga • 11/18/21
Enveric Biosciences announces positive preclinical data for its CBD-based product EV102 treating radiodermatitisProactive Investors • 11/18/21
Enveric Biosciences Announces Positive Preclinical Data for EV102 Radiodermatitis Drug CandidatePRNewsWire • 11/18/21